https://doi.org/10.55788/bd04efaa
What are the risk factors for developing dementia in patients with RA? The goal of a population-based inception cohort study conducted by a group of Mayo Clinic investigators was to elucidate this question [1]. “Our recent studies from population-based cohorts in Olmsted County have shown that even though the overall risk of dementia is increased in patients with RA as compared with the non-RA population, there has been a decline in its incidence in recent decades coinciding with improved control of RA,” Prof. Elena Myasoedova (Mayo Clinic, MN, USA) reported in her presentation. The study included 886 patients ≥50 years who resided in Minnesota and were diagnosed with RA between 1980 and 2014. Follow-up was performed until the end of 2019. For the attribution of incident dementia, at least 2 ICD codes for dementia had to be present ≥30 days apart. Two different Cox proportional hazard models were fitted with model 1 adjusting for age, sex, and year of RA incidence. The other model also included CV risk factors as well as any CV disease.
The mean age of the cohort was 65 years, nearly two thirds were women, and the median follow-up was 8.5 years. During this time, 103 cases of incident dementia occurred. After RA was diagnosed, the risk for dementia rose gradually (2–3% over 5 years). “Similar to the general population, age was one of the risk factors that has been noticed, and older age of RA incidence was associated with a higher incidence of dementia,” Prof. Myasoedova reported. Furthermore, the presence of rheumatoid nodules at baseline and swelling of large joints or anxiety at any time carried an around 2-fold risk-augmentation for dementia. Depression at baseline or ever was an even stronger risk factor with a hazard ratio (HR) between 2.23 and 2.76 depending on timing and model. “Out of the CV risk factors, hypertension stood out for association with dementia,” Prof. Myasoedova remarked. The HRs for baseline hypertension were 1.84 (model 1) and 2.79 (model 2). Among the CV events, baseline heart failure (HR 2.72 and 2.89) and ever ischaemic stroke (HR 3.16 and 3.28) were especially linked to dementia in RA patients in both models. Among the factors that were not associated with dementia were sex, race, education, and RA disease characteristics.
“In summary, clinically active disease as well as hypertension, CV events, depression, and anxiety increased the risk of dementia among patients with RA. Among CV events, ischaemic stroke and heart failure were particularly associated with the risk of dementia,” Prof. Myasoedova concluded. Further studies in this space including the impact of non-steroidal anti-inflammatory drugs (NSAIDs), conventional synthetic, biologic, and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) will add to this emerging story.
- Kodishala C, et al. Active rheumatoid arthritis and associated comorbidities increase risk of dementia: a population-based cohort study. OP0134, EULAR 2022 Congress, 1–4 June, Copenhagen, Denmark.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« VTE in global registry data more common in JAK inhibitor-treated RA patients Next Article
Preventive treatment with methotrexate benefits pre-RA patients with arthralgia »
« VTE in global registry data more common in JAK inhibitor-treated RA patients Next Article
Preventive treatment with methotrexate benefits pre-RA patients with arthralgia »
Table of Contents: EULAR 2022
Featured articles
Late-Breaking Oral Abstracts
TYK2 inhibition: the future of treating lupus erythematosus?
Psoriatic arthritis: significant improvement with bimekizumab
Baricitinib could open the door to oral treatment for juvenile idiopathic arthritis
Sarilumab for polymyalgia rheumatica led to sustained remission and fewer flares
Spotlight on Rheumatoid Arthritis
Comorbid depression comes with a profoundly higher mortality risk in RA
Preventive treatment with methotrexate benefits pre-RA patients with arthralgia
Risk factors for dementia in RA patients discovered
VTE in global registry data more common in JAK inhibitor-treated RA patients
Spondyloarthropathies – Novel Developments
How to treat enthesitis in 2022
Baseline cardiovascular risk linked to higher rates of MACE in PsA and PsO patients receiving tofacitinib
Treat-to-target dose reduction effective in spondyloarthritis
A novel oral treatment possibility for non-radiographic axSpA on the horizon
Many RA and PsA patients have problems with their sex life
What Is Hot in Osteoarthritis?
New treatments in osteoarthritis
OA associated with alcohol and drug abuse
Body mass index increase associated with structural changes in knee OA
What Is New in Lupus and Scleroderma
Inhibition of Bruton’s tyrosine kinase: a new way of approaching SLE?
Pregnancies in SLE: many complications for mothers and their unborn children
Lupus nephritis: Efficient treatment may reduce the risk of kidney disease advancement
Antifibrotic therapy with nintedanib is beneficial for patients with negative prognostic factors
Best of the Posters
Alarmingly low activity in patients with non-inflammatory and inflammatory rheumatic disease
High prevalence of fibromyalgia in patients with inflammatory bowel disease
Related Articles
December 1, 2022
Fast recapture of response with ozanimod after withdrawal in UC
October 27, 2021
Ritlecitinib and brepocitinib are promising JAK inhibitors for UC
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com